8-K: Illumina Reports Preliminary Q4, FY25 Financials

Illumina announced unaudited preliminary financial results for the fourth quarter and fiscal year 2025, reporting revenue growth in Q4 but flat full-year revenue.

Summary

• Preliminary unaudited revenue for the fourth quarter ended December 28, 2025, was approximately $1.155 billion, representing a 5% increase from Q4 2024 (4% on a constant currency basis).
• Ex-China revenue for Q4 2025 was approximately $1.100 billion, up 7% from Q4 2024 (also 7% on a constant currency basis).
• Preliminary GAAP diluted EPS for Q4 2025 ranged from $2.14 to $2.17, while non-GAAP diluted EPS ranged from $1.27 to $1.30.
• Preliminary unaudited revenue for the fiscal year ended December 28, 2025, was approximately $4.34 billion, which was flat compared to fiscal year 2024 (also flat on a constant currency basis).
• Ex-China revenue for FY 2025 was approximately $4.10 billion, up 2% from 2024 (also 2% on a constant currency basis).
• Preliminary GAAP diluted EPS for FY 2025 ranged from $5.42 to $5.45, and non-GAAP diluted EPS ranged from $4.76 to $4.79.
• The company expects to report its full fourth quarter and fiscal year 2025 results on Thursday, February 5, 2026.

Sentiment

Score: 5

Explanation: The preliminary results present a mixed picture with positive Q4 revenue growth but flat full-year revenue. Ongoing strategic initiatives like the SomaLogic acquisition are noted, alongside various operational and geopolitical risks. The sentiment is neutral as the results do not strongly indicate a positive or negative trend without further context or guidance.

Positives

• Fourth quarter 2025 revenue increased by 5% to approximately $1.155 billion compared to Q4 2024.
• Ex-China revenue for Q4 2025 grew by 7% to approximately $1.100 billion, indicating strong performance outside of the Greater China region.

Negatives

• Fiscal year 2025 revenue was approximately $4.34 billion, remaining flat compared to fiscal year 2024, suggesting a lack of overall annual growth.
• Fiscal year 2025 ex-China revenue grew by only 2% to approximately $4.10 billion, indicating slower growth over the full year compared to the fourth quarter.

Risks

• Changes in the rate of growth in the markets served, including the proteomics market.
• The volume, timing, and mix of customer orders among products and services.
• Ability to adjust operating expenses to align with revenue expectations.
• Completion of the proposed acquisition of SomaLogic, Inc. and certain other assets, including obtaining required regulatory approvals (e.g., Hart-Scott-Rodino Act) and satisfying other closing conditions.
• Ability to successfully integrate the SomaLogic Business into existing operations and its technology/products into the portfolio.
• Ability to successfully manage partner and customer relationships in the proteomics market.
• Uncertainty regarding the impact of inclusion on the 'unreliable entities list' by regulatory authorities in China.
• Uncertainty regarding tariffs imposed or threatened by the U.S. government and its trading partners, and other possible trade protection measures.
• Ability to manufacture robust instrumentation and consumables, including SomaLogic Business products.
• Success of products and services competitive with Illumina's own.
• Challenges inherent in developing, manufacturing, and launching new products and services, including expanding or modifying manufacturing operations and reliance on third-party suppliers.
• The impact of recently launched or pre-announced products and services on existing products and services.
• Ability to modify business strategies to accomplish desired operational goals.
• Ability to realize anticipated benefits from prior or future actions to streamline R&D processes, reduce operating expenses, and maximize revenue growth.
• Ability to further develop and commercialize instruments, consumables, and products; deploy new products, services, and applications; and expand markets for technology platforms.
• Risk of additional litigation arising in connection with the GRAIL acquisition.
• Ability to obtain approval by third-party payors to reimburse patients for products.
• Ability to obtain regulatory clearance for products from government agencies.
• Ability to successfully partner with other companies and organizations to develop new products, expand markets, and grow the business.
• Uncertainty, or adverse economic and business conditions, including as a result of slowing or uncertain economic growth or armed conflict.
• The application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments.
• Legislative, regulatory, and economic developments.

Future Outlook

The company provides forward-looking guidance on a non-GAAP basis, including constant currency revenue and growth rates. However, it is unable to provide a reconciliation of forward-looking non-GAAP financial measures to GAAP due to the inherent difficulty in predicting with reasonable certainty the impact of items such as acquisition-related expenses, fair value adjustments, strategic investment gains/losses, potential future asset impairments, restructuring activities, litigation outcomes, and currency exchange rate fluctuations.

Industry Context

Illumina operates as a global leader in DNA sequencing and array-based technologies, serving research, clinical, and applied markets. The company's strategic focus includes expanding into the proteomics market, as evidenced by the pending acquisition of SomaLogic, Inc. This move aligns with broader industry trends towards multi-omics approaches in life sciences and healthcare, aiming to unlock the power of the genome for human health improvement. The mention of risks related to the 'unreliable entities list' in China highlights geopolitical and regulatory challenges impacting global operations in the life sciences sector.

Legal Proceedings

• Risk of additional litigation arising against the company in connection with the GRAIL acquisition.
• Legal contingency accruals are included as an adjustment in non-GAAP financial measures.

Stakeholder Impact

• Shareholders: Impacted by preliminary financial performance, future growth prospects, and risks associated with acquisitions and market conditions.
• Employees: Affected by 'transformational initiatives' which include employee severance costs related to restructuring activities.
• Customers: Potential impact from new product development, market expansion, and the integration of SomaLogic's technology.
• Regulatory Authorities: Involved in the approval process for the SomaLogic acquisition (e.g., Hart-Scott-Rodino Act) and potential implications from inclusion on China's 'unreliable entities list'.

Next Steps

• The company will report its full fourth quarter and fiscal year 2025 results following the close of market on Thursday, February 5, 2026.
• The webcast of the J.P. Morgan Healthcare Conference presentation will remain available for at least 30 days following January 13, 2026, through the Investor Relations section of the company's website.

Key Dates

Recommendation

The preliminary results show a mixed performance with Q4 revenue growth offset by flat full-year revenue. While the company is pursuing strategic growth through the SomaLogic acquisition, significant risks remain, including regulatory approvals, integration challenges, and ongoing litigation related to GRAIL. Investors should hold their positions pending the release of full audited results and further clarity on the company's strategic execution and market outlook.

Keywords

Illumina, ILMN, preliminary financial results, Q4 2025, FY 2025, revenue, EPS, genomics, DNA sequencing, proteomics, SomaLogic acquisition, J.P. Morgan Healthcare Conference, SEC filing